174 related articles for article (PubMed ID: 24947559)
1. Surrogacy assessment using principal stratification and a Gaussian copula model.
Conlon A; Taylor J; Elliott MR
Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
[TBL] [Abstract][Full Text] [Related]
2. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
Taylor JM; Conlon AS; Elliott MR
Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
[TBL] [Abstract][Full Text] [Related]
3. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
Conlon AS; Taylor JM; Elliott MR
Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
[TBL] [Abstract][Full Text] [Related]
4. A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
Li Y; Taylor JM; Elliott MR
Biometrics; 2010 Jun; 66(2):523-31. PubMed ID: 19673864
[TBL] [Abstract][Full Text] [Related]
5. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
Li Y; Taylor JM; Elliott MR; Sargent DJ
Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
[TBL] [Abstract][Full Text] [Related]
6. Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.
Conlon A; Taylor J; Li Y; Diaz-Ordaz K; Elliott M
Stat Med; 2017 Nov; 36(27):4243-4265. PubMed ID: 28786131
[TBL] [Abstract][Full Text] [Related]
7. Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm.
Roberts EK; Elliott MR; Taylor JMG
Stat Med; 2021 Dec; 40(29):6605-6618. PubMed ID: 34528260
[TBL] [Abstract][Full Text] [Related]
8. Accommodating missingness when assessing surrogacy via principal stratification.
Elliott MR; Li Y; Taylor JM
Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
[TBL] [Abstract][Full Text] [Related]
9. Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.
Roberts EK; Elliott MR; Taylor JMG
Biometrics; 2023 Sep; 79(3):1840-1852. PubMed ID: 35833874
[TBL] [Abstract][Full Text] [Related]
10. Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.
Renfro LA; Shang H; Sargent DJ
J Biopharm Stat; 2015; 25(4):857-77. PubMed ID: 24905465
[TBL] [Abstract][Full Text] [Related]
11. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
12. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
13. A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.
Sofeu CL; Emura T; Rondeau V
Biom J; 2021 Feb; 63(2):423-446. PubMed ID: 33006170
[TBL] [Abstract][Full Text] [Related]
14. The individual-level surrogate threshold effect in a causal-inference setting with normally distributed endpoints.
Van der Elst W; Abad AA; Coppenolle H; Meyvisch P; Molenberghs G
Pharm Stat; 2021 Nov; 20(6):1216-1231. PubMed ID: 34018666
[TBL] [Abstract][Full Text] [Related]
15. Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation.
Papanikos T; Thompson JR; Abrams KR; Bujkiewicz S
Stat Med; 2022 Nov; 41(25):4961-4981. PubMed ID: 35932152
[TBL] [Abstract][Full Text] [Related]
16. Surrogacy validation for time-to-event outcomes with illness-death frailty models.
Roberts EK; Elliott MR; Taylor JMG
Biom J; 2024 Jan; 66(1):e2200324. PubMed ID: 37776057
[TBL] [Abstract][Full Text] [Related]
17. A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
Alonso A; Van der Elst W; Molenberghs G
Stat Med; 2018 Dec; 37(29):4525-4538. PubMed ID: 30141219
[TBL] [Abstract][Full Text] [Related]
18. Surrogate markers and joint models for longitudinal and survival data.
Taylor JM; Wang Y
Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
[TBL] [Abstract][Full Text] [Related]
19. Bivariate network meta-analysis for surrogate endpoint evaluation.
Bujkiewicz S; Jackson D; Thompson JR; Turner RM; Städler N; Abrams KR; White IR
Stat Med; 2019 Aug; 38(18):3322-3341. PubMed ID: 31131475
[TBL] [Abstract][Full Text] [Related]
20. Alternative methods to evaluate trial level surrogacy.
Abrahantes JC; Shkedy Z; Molenberghs G
Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
